Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Un-Audited Financial Results For the Quarter and half year ended September 30th, 2026 And Other Matters.

Date: 6th November, 2026 Department of Corporate Service (DCS-CRD), BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. Script Code: 524414 Sub.: Intimation under regulation 29 of SEBI (Listing Obligations and Disclosure Requirements), 2015 for consideration and approval of Un-audited financial results for the quarter and half year ended September 30th, 2026 and other matters. Dear Sir, This is to inform you that, the meeting of the Board of Directors of the Company Norris Medicines Limited scheduled to be held on Saturday, 14th November, 2026 at the Registered office of the Company situated at Plot No.801/P, GIDC, Ankleshwar, Gujarat, 393002, to transact the following business: 1. To consider and approve Un-audited Financial Results for the quarter and half year ended 30th September, 2026 along with Limited Review Report thereof. 2. Any other business with permission of Chair. Further, as communicated earlier, in accordance with Company’s Code of Conduct for Prevention of Insider Trading in securities of the Company and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in securities of the Company is already closed from October 01, 2026 until Forty-Eight (48) hours after declaration of Un-audited financial results for the quarter and half year ended September 30, 2026 on Stock Exchange. Kindly take the same on your records. Thanking You, Yours truly, FOR NORRIS MEDICINES LIMITED VIMAL SHAH MANAGING DIRECTOR DIN: 01506655